Efficacy and safety of concurrent chemoradiotherapy following neoadjuvant chemoimmunotherapy in patients with stage III NSCLC who experienced neoadjuvant failure: A real-world study
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Neoadjuvant chemoimmunotherapy followed by surgery markedly improves outcomes in patients with stage III unresectable non-small cell lung cancer (NSCLC). However, the efficacy and safety of continuing concurrent chemoradiotherapy (cCRT) followed by immunotherapy consolidation in patients who experience failure of neoadjuvant treatment remain unclear. The present real-world study included patients who received cCRT and consolidation immunotherapy after failure of neoadjuvant chemoimmunotherapy at The Second Affiliated Hospital of Nanchang University, Nanchang, China, between May 2018 and August 2024. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were treatment-related adverse events and overall survival (OS). PFS time among patients who experienced neoadjuvant treatment failure was compared with that of patients with unresectable stage III NSCLC treated with the PACIFIC regimen at the same center. A total of 67 patients were included. The median PFS time was 26.0 months (95% CI, 17.8-39.0), with 1-, 2- and 3-year OS rates of 92.5, 79.1 and 77.6%, respectively. The incidence of immune-related adverse events was 34.33% and radiation-related adverse events occurred in 63.2% of patients. Grade ≥3 immunotherapy-related pneumonitis occurred in 5.97% of cases and radiation-related pneumonitis occurred in 4.48%. Comparison with 30 patients previously treated with the PACIFIC regimen showed no significant difference in PFS (HR, 1.155; 95% CI, 0.657-2.032; P=0.615). Notably, treatment-related adverse events were frequent, with bone marrow suppression observed in 86.57% of cases. In conclusion, induction immunotherapy combined with chemotherapy followed by cCRT and immunotherapy consolidation appears effective and safe for patients with stage III NSCLC who have failed neoadjuvant chemoimmunotherapy.
Fields of Study & Subjects
Lung Cancer Diagnosis and Treatment
Lung Cancer Treatments and Mutations
Cancer Immunotherapy and Biomarkers
Publication details
- Journal / source
- Oncology Letters
- Volume
- 31
- Issue
- 5
- Pages
- 1–10
- Publication date
- 30 March 2026
- Language
- EN